Pune: Emcure Pharmaceuticals has reported a consolidated net profit of Rs 153 crore, up 8% year-on-year in Q1FY25. Its revenue from operations rose 17% to Rs 1,815 crore. The company’s domestic business, which accounts for 50% of overall revenues, grew by 14% to Rs 909 crore, led by steady base business performance and aided by a distribution partnership for Sanofi’s Cardiovascular brands, a statement said.
The Sanofi brand portfolio and team are now fully integrated into the company's team, and the performance is in line with its expectations. TNN We also published the following articles recently India Cements clocks Rs 58.47 crore profit in April-June; revenue declines 28.
5% India Cements Ltd reported a consolidated net profit of Rs 58.47 crore in the June 2024 quarter despite a 26% decline in sales volume due to a liquidity crunch. The gain from selling its Parli grinding unit helped offset losses.
Revenue dropped 28.53% to Rs 1,026.76 crore, with negative EBITDA and higher production costs impacting performance further.
Bengaluru techie couple loses Rs 1.53 crore in trading scam, how police recovered Rs 1.4 crore from 50 accounts A Bengaluru tech couple managed to recover Rs 1.
4 crore lost in an online trading scam with the help of local police. The East Division Cybercrime Police in Bengaluru tracked and froze over 50 accounts involved, retrieving the majority of the stolen funds. The police advise caution with online investments and prompt reporting of suspicious activities.
FPIs turn net sellers, withdraw Rs 13,400 crore Foreign investors turned net sellers in Indian equities, withdrawing over Rs 13,400 crore in August. Factors included the unwinding of the yen carry trade and US recession fears. FPIs had previously injected Rs 22,134 crore in 2024.
High market valuations in India and geopolitical tensions also influenced investor behavior. FPIs, however, invested Rs 6,261 crore in the debt market..
